19:54:43 EDT Fri 16 Apr 2021
Enter Symbol
or Name

Login ID:
Zenabis Global Inc
Symbol ZENA
Shares Issued 799,983,791
Close 2021-02-16 C$ 0.18
Recent Sedar Documents

Hexo to acquire Zenabis in a $235M all-share deal

2021-02-16 14:25 ET - News Release

See News Release (C-HEXO) Hexo Corp (2)

Mr. Sebastien St-Louis of Hexo reports


Hexo Corp. and Zenabis Global Inc. have entered into a definitive arrangement agreement under which Hexo will acquire, by way of court-approved plan of arrangement under the Business Corporations Act (British Columbia), all of Zenabis's issued and outstanding common shares in an all-share transaction valued at approximately $235-million. Under the terms of the arrangement agreement, Zenabis shareholders will receive 0.01772 of a Hexo common share in exchange for each Zenabis common share held. The exchange ratio implies a premium per Zenabis common share of approximately 19 per cent based on the 20-day volume-weighted average price of Zenabis common shares on the Toronto Stock Exchange and Hexo common shares on the TSX as of Feb. 12, 2021. Warrants and incentive securities of Zenabis will be adjusted in accordance with their terms to ultimately become exercisable to receive common shares of Hexo based on the share exchange ratio.

The transaction was unanimously approved by the board of directors of each of Hexo and Zenabis (in the case of Zenabis's board of directors, after receiving the unanimous recommendation of a special committee formed for purposes of the transaction), and Zenabis's board of directors unanimously recommends that its shareholders vote in favour of the transaction.

Transaction highlights:

  • Strengthened domestic brands: Based on Hexo's and Zenabis's most recent interim quarterly financial statements and results, and those of the other top-licensed producers in Canada, the combined organization would be a top 3 licensed producer in terms of combined Canadian recreational cannabis sales.
  • Foothold in Europe: The transaction gives Hexo immediate access to the European medical cannabis market through Zenabis's local partner, with an established facility in the European Union supplying pharmaceutical products to the European market. The facility also serves as a European Union good manufacturing practice packaging and distribution centre for medical cannabis products produced in Zenabis's Atholville facility.
  • Accretive synergies: Hexo estimates that the combined entity may realize annual synergies of approximately $20-million within one year of close, through cost-of-good reductions, additional capacity utilization in Hexo's Belleville Centre of Excellence, and selling, general and administrative savings, which, if realized, should allow Hexo to continue its path toward positive earnings.
  • Capacity boost with state-of-the-art cultivation infrastructure: The proposed transaction would give Hexo access to licensed capacity to produce approximately 111,200 kilograms of additional high-quality cannabis annually. The transaction would result in Hexo acquiring two indoor facilities (approximately 635,000 square feet) and access to a 2.1 million-square foot greenhouse facility, totalling approximately 2,735,000 square feet of near-term cultivation space offering diversified growing and production techniques. This provides a platform for growth and foundation from which to strengthen and diversify the company's portfolio of brands.

"We're thrilled to welcome the Zenabis team into the Hexo family. Zenabis has built solid relationships and they share Hexo's vision of bringing exceptional branded cannabis experiences to adults everywhere in Canada and abroad," said Sebastien St-Louis, chief executive officer and co-founder of Hexo. "We are proceeding with this transaction because we believe it should be accretive for our shareholders and it also positions Hexo for accelerated domestic and international growth while supporting near-term requirements for additional licensed capacity. Hexo's growth strategy includes expanding our global presence, and this acquisition is an important step in that direction."

"This is a compelling combination. Our brands and strains strength across Canada, coupled with our international footprint and state-of-the-art low-cost and high-quality cultivation facilities complements Hexo's business, creating an industry leader. Like Hexo, Zenabis believes that the combination should deliver meaningful synergies, a stronger financial position with increased flexibility and should position the combined company to meet growing consumer demand on a national and international basis. I believe this transaction is beneficial to our shareholders, customers, partners and employees. We look forward to working closely with Hexo to complete this transaction," added Shai Altman, CEO of Zenabis.

Additional transaction details

The transaction will require approval by at least 66.66 per cent of the votes cast by the shareholders of Zenabis present at a special meeting of Zenabis shareholders. Hexo has entered into voting support agreements with Zenabis's directors and officers with respect to all Zenabis shares owned by them.

The arrangement agreement includes customary provisions, including non-solicitation provisions, subject to the right of Zenabis to accept a superior proposal in certain circumstances, with Hexo having a period of five business days to exercise a right to match any such superior proposal for Zenabis. The arrangement agreement also provides for a termination fee of $6-million payable by Zenabis to Hexo if the transaction is terminated in certain specified circumstances, as well as reciprocal expense reimbursement fees if the transaction is terminated by either party in certain other specified circumstances.

In addition to the approval by Zenabis's shareholders, the transaction is subject to the receipt of certain regulatory, court and stock exchange approvals, and the satisfaction of customary conditions precedent in transactions of this nature as well as the satisfaction of the following additional conditions precedent:

  1. The termination and unconditional release of the guarantee provided by Zenabis in favour of Bank of Montreal in connection with the disposition of Bevo Farms Ltd. and its subsidiaries announced by Zenabis on Jan. 4, 2021;
  2. The completion of the Bevo sale transaction;
  3. Certain other specified conditions precedent set out in the arrangement agreement.

Upon completion of the transaction, existing Hexo and Zenabis shareholders would respectively own approximately 87.43 per cent and 12.57 per cent of Hexo on a pro forma, fully diluted basis. In addition, Hexo has undertaken in the arrangement agreement, within 90 days of closing of the transaction, to increase the size of its board of directors by one director and cause one of the current directors of Zenabis, selected by Hexo, to be appointed to Hexo's board of directors in accordance with Hexo's constating documents.

Also, Zenabis's wholly owned subsidiary, Zenabis Ltd. has entered into a settlement agreement and release with a customer, pursuant to which the parties have agreed to withdraw from the arbitration proceedings between the parties and release the other party from all past, present and future claims of the parties arising out of the prepaid supply agreement relating to subsequent deliveries of cannabis product.

Contemporaneously with the signature of the arrangement agreement, Zenabis has entered into an agreement with Hexo for the issuance of an unsecured convertible debenture to Hexo in a principal amount of $19.5-million, evidencing both a cash advance extended by Hexo to Zenabis at the end of 2020 as well as a further advance extended to Zenabis contemporaneously with the announcement of the transaction for the purpose of allowing Zenabis to pay the settlement amount pursuant to the settlement agreement. The unsecured convertible debenture bears interest at a rate of 8 per cent per annum and matures on Feb. 15, 2023. The debenture is convertible, in whole or in part, at any time after the earlier of the termination of the arrangement agreement and the then-applicable outside date thereunder, at the option of Hexo, into common shares of Zenabis at a conversion price equal to the five-day volume-weighted average price of the common shares on the TSX for the five trading days prior to the date of conversion. The debenture may be prepaid by Zenabis, at its option and without penalty or premium, at any time after the earlier of the termination of the arrangement agreement and the then-applicable outside date thereunder, subject to Hexo's right to elect to convert the debenture into Zenabis common shares prior to the prepayment. A change of control of Zenabis, other than the transaction with Hexo, shall result in the mandatory conversion of the debenture into common shares of Zenabis at a conversion price equal to the 5-day VWAP where the last day of the 5-day VWAP of the common shares on the TSX shall be the trading day immediately preceding the trading day on which the first of any such change of control transactions is initially publicly announced whether by Zenabis or by the person proposing, intending or agreeing to effect the change-of-control transaction. The unsecured convertible debenture also contains a provision that prevents Hexo from acquiring, at any given time as a result of and upon conversion of the debenture (other than in respect of a mandatory conversion in the context of a change of control transaction), more than 9.9 per cent of Zenabis's common shares. The listing of the Zenabis common shares issuable pursuant to the subscription is subject to the acceptance by the Toronto Stock Exchange.

Further information regarding the transaction, including the key terms and conditions of the unsecured convertible debenture issued to Hexo, will be included in the information circular that Zenabis will prepare, file and mail in due course to its shareholders in connection with its special meeting to be held to consider the transaction. Zenabis will be applying in the coming weeks to the British Columbia Supreme Court to obtain an interim order approving various procedural and related matters in order to convene the special meeting of shareholders in connection with the transaction. The arrangement agreement will be filed under the SEDAR profiles of Zenabis and Hexo on the SEDAR website.

Recommendation of Zenabis's board

The transaction has been unanimously recommended to the Zenabis board of directors by a special committee, comprising independent directors Daniel Burns and Natascha Kiernan, which was formed to investigate strategic alternatives, and to renegotiate and restructure the company's capital. After receiving the recommendation of the special committee and receiving independent financial and legal advice, Zenabis's board of directors has unanimously determined that the transaction is in the best interests of Zenabis and its security holders, and the board of directors unanimously recommends that Zenabis's shareholders vote in favour of the transaction.

The board of directors of Zenabis has obtained a fairness opinion from Echelon Wealth Partners Inc. to the effect that, as of the date of the arrangement agreement, and subject to the assumptions, limitations and qualifications on which such opinion is based, the consideration to be received pursuant to the transaction is fair, from a financial point of view, to the Zenabis shareholders.

Advisers and counsel

Echelon Capital Markets (a member of Echelon Wealth Partners) is acting as financial adviser to Zenabis in connection with the transaction. Stikeman Elliott LLP is acting as legal counsel to Zenabis and to the special committee of the board of directors of Zenabis.

A.G.P./Alliance Global Partners is acting as financial adviser to Hexo and Norton Rose Fulbright Canada LLP is acting as legal counsel to Hexo.

About Hexo Corp.

Hexo is an award-winning consumer packaged goods cannabis company that creates and distributes innovative products to serve the global cannabis market. The company serves the Canadian adult-use markets under its Hexo Cannabis, Up Cannabis and Original Stash brands, and the medical market under Hexo medical cannabis.

About Zenabis Global Inc.

Zenabis is a significant Canadian licensed cultivator of medical and recreational cannabis. Zenabis employs staff from coast to coast, across facilities in Atholville, N.B., Langley, B.C., and Stellarton, N.S. Zenabis currently has 111,200 kilograms of licensed cannabis cultivation space across three licensed facilities in Canada, together with its cannabis import, export and processing joint venture, ZenPharm, operating from Birzebbuga, Malta.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.